Ascentage Pharma Group International (AAPG) Non-Current Receivables (2023 - 2024)
Ascentage Pharma Group International posted quarterly Non-Current Receivables of $3.6 million for Q4 2024, up 270.04% year-on-year from $979433.9 in Q1 2024, and up 270.04% on a QoQ basis from $979433.9 in Q4 2023.
Ascentage Pharma Group International (AAPG) has 2 years of Non-Current Receivables data on file, last reported at $3.6 million in Q4 2024.
- For the quarter ending Q4 2024, Non-Current Receivables rose 270.04% year-over-year to $3.6 million; the trailing twelve-month figure through Dec 2024 stood at $3.6 million (up 270.04% YoY), and the FY2024 full-year result was $3.6 million, up 264.29% from the prior year.
- Non-Current Receivables for Q4 2024 stood at $3.6 million, up from $979433.9 in the prior quarter.
- Across five years, Non-Current Receivables topped out at $3.6 million in Q4 2024 and bottomed at $979433.9 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | 4.49 Mn |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | - |
| 10 | Ascentage Pharma Group International | 1.11 Bn | 937.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 3.62 Mn |
| Dec 31, 2023 | 979,433.90 |